Retatrutide
Human research — investigational use
Research-only / investigational — not FDA approved
Not FDA approved. FDA states that retatrutide cannot be used in compounding under federal law. Source: FDA: concerns with unapproved GLP-1 drugs
What it is
An investigational GIP, GLP-1 and glucagon receptor agonist. Source: Randomized human trial: retatrutide for obesity
What it has been studied for
Weight reduction in a randomized human trial; trial doses are not an approved regimen. Source: Randomized human trial: retatrutide for obesity
Mechanism
Activates receptors for GIP, GLP-1 and glucagon. Source: Randomized human trial: retatrutide for obesity
Documented dosing
Dr. Axe’s educational micro-dose approach
Daily protein target: Not set. Cellular Bloodwork Analysis →
Protect muscle: Include regular resistance training suited to your ability, alongside adequate protein, to help protect muscle while weight comes off. Clinical advisory
Dr. Axe’s educational position is to explore 10–20% of the standard labeled dose. This is arithmetic, not an FDA-labeled regimen or a proven equivalent treatment. This tool does not tell you to cut or change your prescription.
Retatrutide has no FDA-approved label. There is no labeled standard dose, so no standard-dose or micro-dose amount is calculated. FDA status
Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
Gastrointestinal adverse events and increased heart rate were observed in the trial. Source: Randomized human trial: retatrutide for obesity
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.
Sources
- Randomized human trial: retatrutide for obesity · Research publication
- FDA: concerns with unapproved GLP-1 drugs · Clinical / regulatory reference